An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

February 14, 2018 updated by: Bio Products Laboratory
The main objectives of this study are to compare the first and second recovery assessments and recovery when a subject changed batch and to assess whether haemostasis was achieved with Optivate® when treating a bleed. The secondary objectives are to evaluate the clinical tolerance and safety of Optivate®.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Poland
      • Bialystok, Poland
        • Klinika Haematologii, Akademia Medyczna w Bialymstokiu, ul.
      • Gdansk, Poland
        • Klinika Haematologii, Akademia Medyczna w Gdansku, u.
      • Lodz, Poland
        • Klinika Haematologii, Akademia Medyczna w Lodzi, ul.
      • Lublin, Poland
        • Klinika Haematologii, Akademia Medyczna w Lublinie, ul.
      • Poznan, Poland
        • Klinika Haematologii, Akademia Medyczna w Poznaniu, ul.
      • Wroclaw, Poland
        • Klinika Haematologii, Akademia Medyczna w Wroclawiu, ul.
  • United Kingdom
      • Cambridge, United Kingdom, CB2 2QQ
        • Haemophilia Centre, Addenbrooke's Hospital, Hills Road
      • Manchester, United Kingdom, M13 9WL
        • Haemophilia Centre, University Department of Haemophilia Manchester Royal Infirmary
      • Nottingham, United Kingdom, NG7 2UH
        • Haemophilia Centre, University Hospital, Queen's Medical Centre, Clifton Boulevard
      • Sheffield, United Kingdom, S10 2JF
        • Sheffield Haemophilia & Thrombosis Centre, Royal Hallamshire Hospital, Glossop Road
      • Southampton, United Kingdom, SO16 6YD
        • Haemophilia Centre, Southampton General Hospital, Tremona Road

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Immunocompetent with severe Haemophilia A without inhibitor to FVIII, at least 12 years of age, currently receiving FVIII concentrates and have more than 150 exposures. Subjects who require elective surgergy within 6 months of starting on OPTIVATE® are permitted to be included in this study providing that the surgery could be performed using OPTIVATE® as FVIII cover.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Optivate®
Optivate® (Human Coagulation Factor VIII)
Biological: Optivate® (Human Coagulation Factor VIII)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incremental Recovery
Time Frame: Comparison of Baseline with 3 months post-baseline
Comparison of Baseline with 3 months post-baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bio Products Laboratory

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2001

Primary Completion (Actual)

August 1, 2004

Study Registration Dates

First Submitted

September 2, 2014

First Submitted That Met QC Criteria

September 19, 2014

First Posted (Estimate)

September 23, 2014

Study Record Updates

Last Update Posted (Actual)

February 15, 2018

Last Update Submitted That Met QC Criteria

February 14, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 8VWFSE

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Haemophilia A

Clinical Trials on Optivate® (Human Coagulation Factor VIII)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe